Watching Incyte; Traders Circulate Research Report From Unemon Suggesting Novartis Emerges As The Ideal Acquirer, Says "Would Not Be Surprised To See A $105-$110 Deal In The Coming Weeks"
Incyte Corporation +0.40%
Novartis AG Sponsored ADR +0.67%
Incyte Corporation INCY | 74.92 | +0.40% |
Novartis AG Sponsored ADR NVS | 102.52 | +0.67% |
https://unemon.com/ResearchEasy/202411_INCY/20241115_INCY_Takeover_POA.html